Vivos Therapeutics Plans Rights Offering to Raise Capital Amid Going Concern Warning
VVOS sits 26% above its 52-week low of $0.545.
Summary
Vivos Therapeutics announced its intent to file a registration statement for a proposed rights offering to raise additional capital. Preliminary terms indicate an exercise price of the greater of $1.25 or 20% above market, with a subsequent "exploding right" at $1.75 or 40% above market. This follows a series of recent capital raises and debt restructurings, including a $2.39 million private placement in April and a recent agreement to convert up to $4.5 million in senior debt to equity. The company reported a "going concern" warning and Nasdaq delisting risk in its Q1 2026 10-Q filing. This proposed offering is a critical attempt to secure liquidity for operations, but it is subject to SEC effectiveness and other conditions, with no assurance of completion.
At the time of this announcement, VVOS was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.55 to $7.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.